Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-28
2007-08-28
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S422000, C514S423000, C546S208000, C546S276400, C548S538000, C548S518000
Reexamination Certificate
active
10788993
ABSTRACT:
The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
REFERENCES:
patent: 5691356 (1997-11-01), Kimball
patent: 6011155 (2000-01-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6395767 (2002-05-01), Robl et al.
patent: 6544992 (2003-04-01), Dhanak et al.
patent: 2005/0215784 (2005-09-01), Madar et al.
patent: 93/01167 (1993-01-01), None
patent: 97/40832 (1997-11-01), None
patent: 01/34594 (2001-05-01), None
patent: 01/68603 (2001-09-01), None
patent: 01/96295 (2001-12-01), None
patent: 02/30890 (2002-04-01), None
patent: 03/084940 (2003-10-01), None
patent: 03/092605 (2003-11-01), None
patent: 04/016587 (2004-02-01), None
Coutts, Simon J., Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides
Ahren, B., “Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control over a 4-Week Study Period in Type 2 Diabetes”, Diabetes Care, vol. 25, No. 5, May 2002, pp. 869-875.
Deacon, C. F., “Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig”, Diabetes, vol. 47, May 1998, pp. 764-769.
Ohnuma, K., “Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation through CD86 Up-Regulation on APC1”, J. of Immunology, vol. 167, No. 12, 2001, pp. 6745-6755.
Villhauer, Edwin B., “1-3-Hydroxy-1-adamantyl) amino acetyl-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties,” J. Med. Chem. 2003, vol. 46, pp. 2774-2789.
Hughes, T.E., “1-2-3 Cyanopyridin-2-yl) amino ethyl amino acetyl-2-cyano-(S) pyrrolidine), a Slow Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochemistry 1999, vol. 38, pp. 11597-11603.
Djuric Stevan W.
Kopecka Hana A.
Li Xiaofeng
Longenecker Kenton L.
Madar David J.
Abbott Laboratories
Corbin Johanna M.
McKane Joseph K.
Parial Andrew M.
Shiao Rei-tsang
LandOfFree
Pharmaceutical compositions as inhibitors of dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions as inhibitors of dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions as inhibitors of dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3842701